Dose-Dense Chemotherapy for Breast Cancer
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
Clinical Pearls
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
- Early mathematical models suggested scheduling might be a viable alternative strategy to escalating the dose of conventional cytotoxic chemotherapies.
- The big breakthrough in this area was the development of growth factors in the 1980s and 1990s.
- This strategy represents a useful backbone for targeted therapies.
Recent Videos
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Oncotype DX Used for Patients With Breast Cancer to Guide Therapy
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Mitigating Toxicities With Oral SERDs and Other Breast Cancer Therapies
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
Shortened Radiation Trial Advances Breast Cancer Treatment
Understanding the Significance of ESR1 Mutations in Breast Cancer
Related Content
